Stem Cell Therapeutics changes name to Trillium Therapeutics
Stem Cell Therapeutics Corp. (TSX: SSS; OTCQX: SCTPF), an immuno-oncology company developing innovative therapies for the treatment of cancer, has filed articles of amalgamation to merge with its wholly-owned subsidiary Trillium Therapeutics Inc. The combined company has adopted the Trillium name.
“The use of “Stem Cell” in our company name did not properly reflect our business, which is strongly focused on the immuno-oncology area, such as our checkpoint inhibitor program targeting the CD47/SIRPa immunoregulatory axis,” said Dr. Niclas Stiernholm, CEO of Trillium Therapeutics. “Trillium enjoyed a solid reputation in the biopharmaceutical industry for its high quality immunotherapy research, exemplified by a decade of strong industry and academic partnerships. We will clearly benefit from this brand recognition with our return to the Trillium name.”
Stem Cell Therapeutics has received conditional approval for the name change from the TSX. Trillium Therapeutics stock will trade under the symbol “TR”.
On April 9, 2013, Stem Cell Therapeutics acquired vc-backed Trillium, a biopharmaceutical company specializing inimmune regulation and the development of cancer stem cell-related therapeutics for $2.58 million in cash and stock.
Trillium had previously raised over $20 million from its venture capital backers.